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Abstract  38 
 39 
Purpose:   40 
This study aimed to examine fracture risk in patients with late-onset psoriasis and 41 
investigate the effect of methotrexate on fracture risk.  42 
Methods:  43 
A cohort study was conducted using primary care records from the UK-based Clinical 44 
Practice Research Datalink. Individuals aged 40 years and over, with incident (new onset) 45 
diagnoses of psoriasis were identified from 1990–2004 and followed up until 2015. For each 46 
exposed individual, up to four age-, gender- and practice-matched controls were randomly 47 
selected. Incidence rates of fragility fracture (hip, vertebral, spine, radius or unspecified site) 48 
per 10,000 person-years were calculated and hazard rates compared to the unexposed 49 
using Cox regression models. The risk of fracture was also estimated, within the exposed 50 
group for patients receiving/not receiving methotrexate.  51 
Results:  52 
24,219 patients with psoriasis and 94,820 controls were identified. The absolute rate of 53 
fracture in psoriasis patients was 58 per 10,000 person-years (95% confidence interval (CI): 54 
55, 61) and 53 per 10,000 person-years in the matched controls ((CI): 52, 54). Psoriasis 55 
patients had a 10% increased risk of fracture compared to their matched controls (hazard 56 
ratio (HR) = 1.10; 95% CI: 1.04, 1.16). Methotrexate use was not associated with increased 57 
risk (0.91 (0.72, 1.15)). 58 
Conclusions:  59 
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Identifying additional clinical factors associated with increased fracture risk is important in 60 
improving fracture risk stratification. Further work is needed to determine the relationship 61 
between age of onset of psoriasis and fracture risk, explore causative explanations and 62 
identify if existing fracture risk stratification tools underestimate fracture risk in patients 63 
with psoriasis.  64 
Keywords: psoriasis, fracture, osteoporosis, methotrexate  65 
 66 
Mini abstract (max 50 words) 67 
This study aimed to examine fracture risk in patients with late-onset psoriasis. A cohort 68 
study was conducted using primary care records from the Clinical Practice Research 69 
Datalink. Psoriasis patients had a 10% increased risk of fracture compared to matched 70 
controls (hazard ratio (HR) = 1.10; 95% CI: 1.04, 1.16).  71 
  72 
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Introduction  73 
Psoriasis is a common inflammatory skin condition, usually characterised by well-delineated 74 
red, scaly plaques. Between 7 and 42% of patients with psoriasis have associated 75 
inflammatory arthritis [1] (psoriatic arthritis: PsA). Psoriasis is associated with several co-76 
morbidities including cardiovascular disease, hypertension, obesity, diabetes, and an excess 77 
risk of mortality [2]. As with other inflammatory conditions such as rheumatoid arthritis (RA) 78 
[3], it has been theorised that psoriasis may be associated with an increased risk of fragility 79 
fracture. Three potential mechanisms link inflammatory diseases with osteoporosis and 80 
accelerated bone loss. First, there is a direct effect of pro-inflammatory cytokines (such as 81 
IL1, IL6, IL11, IL15, IL17 and TNFα) on bone; these act as primary mediators of accelerated 82 
bone loss [4]. Second, some inflammatory disease treatments are thought to be detrimental 83 
to bone health. With relevance to the treatment of psoriasis, methotrexate inhibits 84 
osteoblastic function, predisposing to fracture [5]. Third, immobility – which may be 85 
associated with chronic, particularly musculoskeletal, inflammatory conditions – results in 86 
increased bone resorption leading to osteoporosis.  87 
However, previous studies examining bone health and fracture risk in patients with psoriasis 88 
have provided conflicting results. An increase in prevalence of osteoporosis has been 89 
reported in one cohort study [6], whilst another cohort demonstrated no association with 90 
either fracture or reduced bone mineral density [7]. More recently, a large population-based 91 
study has suggested that patients with mild psoriasis have a 13% increased risk of hip 92 
fracture [8].  93 
A possible explanation for these conflicting results is the heterogeneous nature of the 94 
condition. Psoriasis has a bimodal peak of incidence [9] and there is some evidence that 95 
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early-onset psoriasis (presenting in individuals aged under 40) and late-onset psoriasis (aged 96 
40 years and over) are distinct conditions with clinical, genetic and immunocytochemical 97 
profiles [10].  98 
Further questions persist regarding fracture risk in PsA and the influence on fracture risk of 99 
drugs used to treat psoriasis. For patients with psoriasis requiring systemic treatment, and 100 
patients with PsA failing to respond to non-steroidal anti-inflammatory drugs, methotrexate 101 
is recommended as the first-line drug of choice [11, 12]. Methotrexate has been reported to 102 
cause fractures [5], although its use was not associated with increased fracture risk in a 103 
large Danish case-control study [13]. Patients with PsA could be expected to be at higher 104 
risk of fracture owing to higher inflammatory burden, more common methotrexate use 105 
and/or restricted mobility; however, Odgie et al did not find patients with PsA were at 106 
higher risk than patients with psoriasis in their population-based study [8].  107 
Understanding factors associated with increased risk is important to allow screening to be 108 
targeted at the most appropriate individuals. Current guidance for the management and 109 
identification of co-morbidities in patients with psoriasis do not address bone health [2, 11].  110 
This study aimed to examine fracture risk in patients with late-onset psoriasis and PsA and 111 
investigate the effect of methotrexate on this risk.  112 
 113 
Materials and Methods 114 
We conducted a cohort study using data from the Clinical Practice Research Datalink (CPRD), 115 
a large UK primary care medical record database of anonymised patients that covers more 116 
than 6.9% of the UK population and is representative in terms of age and sex distribution 117 
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[14]. Practices contributing data to CPRD receive training on recording information and the 118 
database is subjected to quality checks, with data from a practice only being used when it 119 
has reached a certain standard of quality, defined as being up-to-standard (UTS). 120 
The exposed population was defined as patients aged over 40 years with an incident (new 121 
onset) diagnosis (Read code) of psoriasis (supplementary table 1) between 1990 and 2004. 122 
Huerta et al. [15] carried out external validation of psoriasis diagnosis in CPRD and found 123 
that 82% of psoriasis diagnoses were verified by physicians. Each patient was assigned an 124 
index date corresponding to the date of their disease diagnosis. 125 
For each exposed patient, up to four controls were randomly selected matched on age 126 
(three year age bands), gender and general practice, with the controls’ index date anchored 127 
to that of their matched exposed patient. Controls were defined as those without psoriasis 128 
and without other common inflammatory musculoskeletal conditions (polymyalgia 129 
rheumatica (PMR), giant cell arteritis (GCA), gout, ankylosing spondylitis (AS), inflammatory 130 
bowel disease, systemic lupus erythematosus, RA and PsA) prior to their index date.   131 
The study end date was defined as the earliest date of: the patient’s death; date the patient 132 
transferred out of the practice; date of last data collection from that practice; 31st August 133 
2015 and date of first fracture.  134 
The event of interest was time from the index date until the first diagnosis of fracture. Read 135 
codes for fractures at sites of major osteoporotic fracture were selected (vertebrae, 136 
humerus, wrist and hip) [16] in addition to Read codes for fragility fractures of unspecified 137 
site. Patients with the following were excluded: Read code for fracture (as previously 138 
defined) prior to their index date; Read code for fracture in the first six months of their 139 
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registration with the practice (assumed to be prevalent cases); less than 12 months of UTS 140 
follow-up prior to index date and less than 3 years of UTS follow-up after index date. 141 
We extracted information on patient demographics (age and gender) at their index date, on 142 
lifestyle-related characteristics (body mass index (BMI), smoking status and alcohol 143 
consumption) using the measurement nearest to their index date (ever prior to index and 144 
up to 1 year after) and on comorbidities (using the Charlson comorbidity index) and the 145 
prescription of medications (corticosteroids, methotrexate, bisphosphonates and proton-146 
pump inhibitors (PPI)) prior to the outcome for both exposed and non-exposed. Those with 147 
missing information on BMI, smoking and alcohol were included in separate categories.  148 
Incidence rates were expressed as the number of incident fractures per 10,000 person-149 
years. Cox proportional hazards models were used to obtain estimates of hazard ratios with 150 
95% confidence intervals to assess the association between psoriasis exposure and time to 151 
first fracture, based on robust standard errors to account for matching. Unadjusted 152 
estimates were obtained, followed by adjustment for confounding factors which affected 153 
estimates by >10% (to avoid over-adjustment) from age, gender, BMI, alcohol, smoking, 154 
Charlson comorbidity index, bisphosphonate, glucocorticoid and PPI use. The proportional 155 
hazards assumption was tested using Schoenfeld residuals. Subgroup analyses were 156 
conducted by fracture site, disease severity, age and gender. Disease severity was 157 
categorised into three mutually exclusive groups: mild-moderate, severe (defined as 158 
prescription for systemic medication (e.g. methotrexate, ciclosporin, relevant biologic drug 159 
or psoralens) or having phototherapy Read code) and PsA (≥ 1 PsA Read code). The effect of 160 
methotrexate use on fracture risk within psoriasis patients was evaluated by estimating 161 
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hazard ratios within the exposed group, comparing patients with any methotrexate use to 162 
those with none. 163 
Sensitivity analyses undertaken in patients with no missing category for smoking, alcohol 164 
use and BMI were compared to the main results. Sensitivity analyses were also conducted to 165 
address the potential misclassification of PsA, by including individuals with both psoriasis 166 
and either RA or AS in this category.  167 
All analyses were performed using Stata/MP 14.2 (Stata Corporation, TX. USA). This study 168 
was approved by the Independent Scientific Advisory Committee of CPRD (protocol 169 
15_165RA). 170 
 171 
Results 172 
The basic characteristics of the exposed and non-exposed populations are given in Table 1. 173 
Our study included 24,219 patients with late-onset psoriasis individually matched to 94,820 174 
non-exposed patients, followed up for a median of 11.3 years (Interquartile range IQR (7.32, 175 
14.17). Of the patients with a diagnosis of psoriasis, 1008 (4.2%) also had PsA and of the 176 
remaining 23,211 with psoriasis alone, 802 (3.5%) had severe disease and 22,409 (96.5%) 177 
had mild-moderate disease. Compared to controls, psoriasis patients had higher BMI 178 
(>30kg/m2: 18.2% vs. 13.7%), were more likely to smoke than their matched controls (25.8% 179 
vs. 19.4%) and more likely to consume 10 or more units of alcohol weekly (20.7% vs 16.8%).  180 
PPI and methotrexate prescriptions were more common among patients with psoriasis 181 
compared to controls (49.8% vs. 42.0% and 4.5% vs 0.6% respectively). 182 
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Within the exposed population, 1576 (6.5%) patients had a fracture after diagnosis. This 183 
corresponded to an absolute rate of 58 per 10,000 (95% confidence interval (CI): 55, 61) 184 
person-years (Table 2). Within the non-exposed population, the absolute rate was 53 (52, 185 
54) per 10,000 person years. Psoriasis patients had a 10% increased risk of fracture 186 
compared to their matched controls (hazard ratio (HR) = 1.10; 95% CI: 1.04, 1.16). After 187 
adjustment for confounding factors, hazard ratios were increased/decreased by less than 188 
10% and hence unadjusted estimates are discussed here, however estimates adjusted for all 189 
of the confounding factors listed are presented in Table 2 for comparison. The increased risk 190 
compared to controls was slightly higher in males (HR (95% CI): 1.22 (1.09, 1.36)) than 191 
females (HR (95% CI): 1.07 (1.00, 1.14)). The increased risk of fracture was similar in the 192 
vertebra (HR (95% CI): 1.15 (0.97, 1.35)), hip (1.14 (1.02, 1.27)) and humerus (1.20 (1.04, 193 
1.38)). 1082 (4.5%) psoriasis patients received a methotrexate prescription and there was 194 
no significant difference in fracture risk between those receiving and not receiving 195 
methotrexate (HR (95% CI): 0.91 (0.72, 1.15)). 196 
Patients with severe disease had similar risk of fracture to those with mild-moderate 197 
disease. The estimate of fracture risk in the PsA population was higher than the risk in those 198 
with mild-moderate psoriasis, but non-significant (1.26 (0.95, 1.65)).  199 
The sensitivity analysis which excluded those with missing categories for smoking, alcohol 200 
use and BMI found similar results (data not presented).The sensitivity analysis including 201 
patients with psoriasis and PsA or RA and/or AS Read Codes yielded similar results (HR (95% 202 
CI): 1.21 (0.96, 1.54)). 203 
 204 
Discussion 205 
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This is the first study within CPRD to quantify the increased risk of fragility fracture in people 206 
with late onset psoriasis, and to examine the effect of gender and methotrexate. The 207 
increased risk was higher in men than women, appeared to be higher in patients with PsA, 208 
although this was not statistically significant, and not altered by methotrexate prescription. 209 
Pro-inflammatory cytokines such as IL-17 are known to be associated with osteoclastic bone 232 
resorption in other chronic inflammatory diseases such as rheumatoid arthritis [4], leading 233 
to osteoporosis and propensity to fracture. It is therefore possible that in psoriasis and 234 
psoriatic arthritis, in which IL-17 plays a key role, this mechanism in part explains the 235 
increased risk of fracture observed. Furthermore, this study demonstrates the prevalence of 236 
risk factors for fragility fractures are higher in patients with psoriasis, such as smoking, 237 
alcohol, and use of protein pump inhibitors and glucocorticoids. Oral glucocorticoids are not 238 
a treatment modality for psoriasis, but may precipitate the condition; this may explain the 239 
apparent higher rate of steroid use in exposed patents. 240 
An increased fracture risk in men with psoriasis has not previously been reported. This may 241 
be explained by increased prevalence of risk factors for fracture in men such as excess 242 
alcohol consumption [17], which was also observed in our data, although adjustment for 243 
these variables did not alter estimates. We found fracture risk in patients with PsA to be 244 
higher, compared to patients with psoriasis alone, although non-significant. This finding was 245 
as expected although different to that in the previous population study where the risk of 246 
fracture appeared lower in those with PsA [8]. Both our study, and that in the THIN 247 
database, identified relatively low numbers of patients with PsA. 248 
A previous study examining the incidence of metabolic comorbidities in psoriasis 249 
demonstrated that age of onset was associated with risk, with patients with early onset 250 
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psoriasis being of higher risk of developing complications such as non-alcoholic fatty liver 251 
disease [18]. This, theoretically could be due to longer exposure to pro-inflammatory 252 
cytokines. However, in our study, patients with mild-moderate late-onset psoriasis had 253 
higher risk of all fractures than that demonstrated in the recently published study using The 254 
Health Improvement Network (THIN) database which included patients with any age of 255 
onset (10% increased risk, compared with 7%) [8]. The THIN study [8] categorised fractures 256 
into all sites, including non-fragility fracture sites e.g. skull which may explain the difference 257 
in rates. Furthermore, genetic differences have been observed in early and late onset 258 
disease, also associated with gender, which may play a role in fracture risk [19]. 259 
By utilising CPRD and selecting all incident cases during the study period, our findings are 260 
generalizable to the wider UK population. However, our study is subject to some limitations. 261 
As in any database study, it is possible that residual confounding remains and we could not 262 
account for factors such as immobility or vitamin D.  Although missing data were present in 263 
BMI, smoking status and alcohol use, which could bias our estimates,  a sensitivity analysis 264 
of complete cases did not change our estimates. We relied on general practitioner (GP) 265 
diagnoses of psoriasis and fracture: however the diagnoses of psoriasis, hip and spinal 266 
fractures have previously been validated in CPRD [15, 20]. Although we cannot account for 267 
drugs prescribed in secondary care e.g. biologic treatments, in practice, non-biologic 268 
treatments are routinely used prior to biologics and hence most patients will be identified as 269 
‘severe’ and we used other proxy measures for severity. The proportion of patients with PsA 270 
was lower than expected raising the possibility of misclassification; however, sensitivity 271 
analysis to account for this did not change our findings. The small number of patients 272 
classified as having PsA or severe psoriasis has influenced the precision of risk estimates in 273 
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these populations. Finally, there is a risk of misclassification for incident cases of late onset 274 
psoriasis that may actually represent recurrence of early onset disease.  275 
In summary, this study suggests that further work is needed to explore the association 276 
between age of onset of psoriasis and fracture risk and to explore possible causative 277 
mechanisms. As has occurred in diabetes [21], further work is now needed to examine 278 
whether existing risk stratification tools such as FRAX underestimate fracture risk in patients 279 
with psoriasis or PsA. 280 
 281 
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Table 1: Basic characteristics of psoriasis exposed and non-exposed patients 
Variables Exposed 
N=24,219 
n (%) 
Non-exposed 
N=94,820 
n (%) 
Follow up time; median (IQR) 11.29 (7.32, 14.17) 11.38 (7.52, 14.33) 
   
Male: n (%) 12,320 (50.87) 48,309 (50.95) 
Mean age (SD) 58.94 (11.83) 58.83 (11.57) 
BMI – Kg/m2   
<18.5 224 (0.92) 931 (0.98) 
18.5-25 6,828 (28.19) 28,678 (30.24) 
25-30 7,528 (31.08) 26,699 (28.16) 
>30 4,410 (18.21) 13,031 (13.74) 
Missing 5,229 (21.59) 25,481 (26.87) 
Smoking status    
Current smokers 6,259 (25.84) 18,425 (19.43) 
Never/Ex-smokers 14,915 (61.58) 59,285 (62.52) 
Missing 3,045 (12.57) 17,110 (18.04) 
Alcohol (units per week)   
Never/Ex-drinker  4,323 (17.85) 16,117 (17.00) 
1-9 6,174 (25.49) 24,588 (25.93) 
≥10 5,005 (20.67) 15,884 (16.75) 
Missing 8,717 (35.99) 38,231 (40.23) 
Steroid prescription during study period   
None 17,818 (73.57) 76,927 (81.13) 
1 prescription 1,719 (7.10) 5,481 (5.78) 
More than 1 prescription 4,682 (19.33) 12,412 (13.09) 
Median no. steroids prescriptions (IQR) 4 (1, 13) 3 (1, 10) 
Median Charlson comorbidity index 1  (0, 3) 1 (0, 2) 
Methotrexate use 1082 (4.47) 569 (0.60) 
Bisphosphonates use 288 (1.19) 832 (0.88) 
PPI use 12,057 (49.78) 39,793 (41.97) 
Lithium use 90 (0.37) 202 (0.21) 
 
 
16 
 
Table 2: Incidence rates (95% CI) per 10,000 person years of fracture and hazard ratios (95% CI) for fractures in exposed 
17 
 
Variables Exposed Non-exposed HR (95% CI) 
Adjusted HR 
(95%CI)‡ 
 
Number with 
fracture 
Rate (95% CI) per 
10,000 person-years 
Number with 
fracture 
Rate (95% CI) per 
10,000 person-years 
  
Overall 1576 57.99 (55.20, 60.93) 5693 52.87 (51.52, 54.26) 1.10 (1.04, 1.16) 1.14 (1.08, 1.21) 
Gender       
Male 415 30.88 (28.05, 34.00) 1356 25.49 (24.17, 26.88) 1.22 (1.09, 1.36) 1.24 (1.11, 1.38) 
Female 1161 84.52 (79.80, 89.52) 4337 79.62 (77.28, 82.02) 1.07 (1.00, 1.14) 1.12 (1.05, 1.19) 
Age       
40-49 198 24.30 (21.14, 27.94) 686 21.64 (20.08, 23.32) 1.12 (0.96, 1.32) 1.15 (0.98, 1.35) 
50-59 334 40.35 (36.25, 44.92) 1238 37.60 (35.56, 39.75) 1.08 (0.95, 1.22) 1.12 (0.99, 1.27) 
60-69 440 67.51 (61.49, 74.12) 1618 61.39 (58.47, 64.45) 1.11 (1.00, 1.23) 1.15 (1.03, 1.28) 
70-79 448 130.20 (118.69, 142.84) 1606 115.26 (109.76, 121.04) 1.15 (1.03, 1.27) 1.21 (1.09, 1.35) 
≥80 156 196.63 (168.07, 230.04) 545 198.46 (182.48, 215.84) 0.99 (0.83, 1.18) 1.04 (0.87, 1.25) 
Fracture site       
Wrist 557 20.50 (18.86, 22.27) 2113 19.62 (18.81, 20.48) 1.05 (0.95, 1.15) 1.16 (1.05, 1.27) 
Vertebra 179 6.59 (5.69, 7.63) 621 5.77 (5.33, 6.24) 1.15 (0.97, 1.35) 1.14 (0.96, 1.34) 
Hip 413 15.20 (13.80, 16.74) 1445 13.42 (12.75, 14.13) 1.14 (1.02, 1.27) 1.17 (1.05, 1.31) 
Humerus 246 9.05 (7.99, 10.26) 813 7.55 (7.05, 8.09) 1.20 (1.04, 1.38) 1.22 (1.06, 1.41) 
Non-specified 181 6.66 (5.76, 7.70) 701 6.51 (6.05, 7.01) 1.03 (0.88, 1.22) 1.03 (0.87, 1.21) 
Severity       
Severe psoriasis 56 57.28 (44.08, 74.43) 184 52.44 (45.38, 60.59) 1.09 (0.81, 1.45) 1.15 (0.83, 1.60) 
Mild-moderate 
psoriasis 
1455 58.19 (55.27, 61.26) 5312 53.30 (51.89, 54.76) 1.10 (1.04, 1.16) 1.13 (1.07, 1.20) 
Psoriasis and 
psoriatic 
arthritis 
65 54.46 (42.71, 69.45) 197 43.70 (38.00, 50.25) 1.26 (0.95, 1.65) 1.62 (1.20, 2.18) 
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‡Adjusted for age, gender, BMI, alcohol consumption, smoking status, Charlson comorbidity, bisphosphonate, glucocorticoid and PPI use 
